| http://www.w3.org/ns/prov#value | - The company indicated that sales will be in the range of $22.6 billion to $23.4 billion, with growth in Japan and emerging markets, particularly China, as well as from products including Humalog, Humulin, Cialis, Forteo and Cymbalta outside the US. Lechleiter added that with 13 potential new medicines in Phase III testing...
|
